May 3, 2020
CEO of Akoya Biosciences, Brian McKelligon, discusses how
technology can improve and advance research in the field of
immuno-oncology.
In this episode, you will learn:
In essence, immuno-oncology is the study of how to treat cancer
by unlocking the power of the immune system and leveraging it
against metastatic processes.
In recent years, therapeutic modalities in this field have been
exploding, and the goal at Akoya is to provide technology to
scientists in academic, biopharmaceutical, and government
institutions who are developing these therapies. The cornerstone of
Akoya’s technology is the identification of biomarkers predictive
of the success of immuno-oncology therapy for individual
patients.
Instead of merely detecting whether or not a biomarker is
present, McKelligon emphasizes the importance of locating where in
the tissues they are present, determining how many are present, and
obtaining proximal measurements between biomarkers.
Standard technologies are only able to detect up to three
biomarkers at a time, whereas the Akoya technology allows for the
detection of 30 to 50 at a time, making it an excellent and
much-needed tool for next generation tissue analysis. This
technology will allow scientists to locate more predictive
biomarkers, which will in turn benefit health economics and patient
care.
Learn more at https://akoyabio.com/.